Clinical Trial Update: eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and tolerability of adding lacosamide (Vimpat) to levetiracetam in epilepsy has completed with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• LEVETIRACETAM (levetiracetam)
• Vimpat (lacosamide)

Snippet

Sponsor: UCB Pharma | Conditions: Epilepsy | Phase 3 | Status: COMPLETED | Results posted: 2014-11-26